Investor Presentaiton
IBI-362 (GLP-1/GCGR) Development Plan Overview
Weekly GLP-1/GCGR with Potential BIC Profile for Obesity and Diabetics
•
Percent CFB in body weight (%),
LS mean (SE)
IBI-362 Differentiated Advantages
Weekly injectable OXM analog via optimized ratio of activation of
GLP-1 and Glucagon receptor vs. binding GLP-1 only
Dual activation of GLP-1/GCGR may bring multiple metabolic and
CV benefit include:
1) blood glucose reduction and weight loss
2) blood pressure and Lipid spectrum improvement;
improvement on Liver fat accumulation, inflammation and fibrosis
3)
4)
potential CV risk reduction
Clinical Highlights
Percentage Change in body weight
N
0
N
+
through week 12
-8-
0
4
8
12
Time (weeks)
0.6%
CFB in body weight (kg),
LS mean (SE)
2
CFB in body weight through week 12
-8.
T
0
4
8
12
Time (weeks)
Clinical Highlights
Promising data of IBI-362 in both weight loss and glucose control in Ph1b
studies (Obesity / Diabetes)
1) Results of the Phase 1b study of IBI362 in overweight/obesity (published at ADA
2021 and Eclinical Medicine) showed a favorable safety profile and robust efficacy,
including weight loss and multiple metabolic benefits, underlying the advantages
and potential of IBI362 as a best-in-class new generation GLP-1 based drug. The
observation in extended cohort (higher dose level) were even more efficacious.
2) Results of the Phase 1b study of IBI362 in patients in Type 2 diabetes were very
impressive, and will be disclosed at 2021 IDF annual meeting.
Clinical
IBI-362 Development Program Overview
progress
Obesity:
Released Phase 1b data in obesity at ADA 2021 and Eclinical
Medicine
FPFD in Phase 2 study for IBI-362 in obesity in 2021.06
0.37 kg
IBI362 3.0 mg
IBI362 4.5 mg
Diabetes:
-3.80 kg
-5.12 kg
-5.77 kg
IBI362 6.0 mg
Pooled placebo
2021 plan
6
-4.81%
-6.05%
-6.40%
6
Enrolled first patient in Phase 2 study for IBI-362 in
diabetes in 2021.08
Plan to release Phase 1b data in diabetics at IDF 2021
First-in-class OXM3 in Phase 2 stage in China that has demonstrated strong weight deduction effect as well as multiple metabolic benefit in
the Phase 1b study for obesity subjects, and demonstrated strong glucose control and other metabolic improvements in the Phase 1b study
for diabetics patients.
Innovent
Confidential
Copyright©2021 Innovent Biologics
35View entire presentation